The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt.biotech. Regulatory News (IBT)

Share Price Information for Int.biotech. (IBT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 635.00
Bid: 626.00
Ask: 638.00
Change: 0.00 (0.00%)
Spread: 12.00 (1.917%)
Open: 635.00
High: 0.00
Low: 0.00
Prev. Close: 635.00
IBT Live PriceLast checked at -
International Biotechnology is an Investment Trust

To achieve capital growth through investing in high growth, development stage biotechnology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Joint Lead Investment Managers

15 Mar 2021 12:43

RNS Number : 2914S
Intl. Biotechnology Trust PLC
15 March 2021
 

15 March 2021

 

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

("IBT" or the "Company")

 

APPOINTMENT OF JOINT LEAD INVESTMENT MANAGERS

 

The Board of International Biotechnology Trust (the "Company") and SV Health Investors announce that Carl Harald Janson has decided to step back from his role as Lead Investment Manager after seven successful years at the Company's helm.

Lead responsibility for portfolio management will transition to Ailsa Craig and Marek Poszepczynski and the Board has approved them as joint Lead Investment Managers. Following a handover period, Carl Harald will remain as a Senior Adviser to SV Health Investors. Kate Bingham will remain the Investment Manager of the Company's unquoted portfolio.

Ailsa and Marek have played key roles working alongside Carl Harald in the investment management team of the Company, and both have many years' experience in the biotechnology and healthcare industry and are scientifically trained. Ailsa has been an investment manager at SV Health Investors for 15 years, having previously worked as a healthcare research analyst. Marek joined SV Health Investors in 2014 as an investment manager, having previously worked for a decade in business development within the biotech industry, structuring and creating M&A transactions and IPOs as well as founding and managing several biotech companies.

Jim Horsburgh, Chairman, commented: "We thank Carl Harald for the pivotal role he has played over the past seven years leading International Biotechnology Trust to an all-time high in NAV terms in 2020, and wish him well for the future. Ailsa and Marek are extremely capable and long-standing core members of our investment team and we are confident that they will continue to deliver strong returns to shareholders."

 

 

For further information contact:

 

Broker - Numis

 

Nathan Brown +44 (0)20 7260 1426 / +44 (0)7795 964 870

 

Vicki Paine +44 (0)20 7260 1256 / +44 (0)78 8431 1486

 

 

Company Secretary - Link Company Matters

 

Claire Jackson +44 (0)7821 843993

 

 

LEI: 213800N1QUJ744P76D11

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCLELFFFXLZBBL
Date   Source Headline
5th Apr 20234:58 pmRNSTransaction in Own Shares
4th Apr 20235:00 pmRNSTransaction in Own Shares
3rd Apr 20234:40 pmRNSTransaction in Own Shares
3rd Apr 20239:58 amRNSTotal Voting Rights
3rd Apr 20237:00 amRNSCompliance with the Market Abuse Regulation
31st Mar 20234:57 pmRNSTransaction in Own Shares
29th Mar 20235:44 pmRNSTransaction in Own Shares
24th Mar 20235:34 pmRNSTransaction in Own Shares
22nd Mar 20235:11 pmRNSTransaction in Own Shares
21st Mar 20238:00 amRNSPortfolio Update
17th Mar 20234:54 pmRNSTransaction in Own Shares
16th Mar 20235:10 pmRNSTransaction in Own Shares
15th Mar 20235:12 pmRNSTransaction in Own Shares
15th Mar 20234:24 pmRNSTransaction in Own Shares
13th Mar 20234:10 pmRNSTransaction in Own Shares
13th Mar 202312:32 pmRNSPortfolio Update
7th Mar 20234:59 pmRNSTransaction in Own Shares
2nd Mar 20235:29 pmRNSTransaction in Own Shares
21st Feb 20237:00 amRNSPortfolio Update
13th Feb 20237:00 amRNSInvestment Management Update
7th Feb 20239:00 amRNSDirector Declaration
2nd Feb 20237:00 amRNSPortfolio Update
23rd Jan 20235:22 pmRNSAppointment of Non-executive Director
23rd Jan 20237:00 amRNSPortfolio Update
3rd Jan 20237:00 amRNSBlock listing Interim Review
19th Dec 20229:00 amRNSPortfolio Update
14th Dec 20227:00 amRNSPortfolio Update
12th Dec 20222:23 pmRNSPortfolio Update
8th Dec 20227:47 amEQSHardman & Co Research on International Biotechnology Trust (IBT): Low FDA activity may drive further M&A
6th Dec 20224:24 pmRNSDividend Declaration
6th Dec 20224:18 pmRNSResult of AGM
1st Dec 20222:38 pmRNSTotal Voting Rights
17th Nov 20228:00 amRNSPortfolio Update
9th Nov 20224:48 pmRNSTransaction in Own Shares
8th Nov 20224:41 pmRNSTransaction in Own Shares
7th Nov 20225:20 pmRNSTransaction in Own Shares
4th Nov 20224:40 pmRNSTransaction in Own Shares
3rd Nov 20224:57 pmRNSTransaction in Own Shares
1st Nov 20225:22 pmRNSTransaction in Own Shares
1st Nov 202211:26 amRNSTotal Voting Rights
1st Nov 20227:00 amRNSAnnual Financial Report
31st Oct 20225:20 pmRNSTransaction in Own Shares
27th Oct 20225:33 pmRNSTransaction in Own Shares
26th Oct 20224:39 pmRNSTransaction in Own Shares
25th Oct 20228:00 amRNSPortfolio Update
24th Oct 20225:12 pmRNSTransaction in Own Shares
18th Oct 20225:36 pmRNSTransaction in Own Shares
17th Oct 20221:16 pmRNSTransaction in Own Shares
13th Oct 20225:55 pmRNSTransaction in Own Shares
13th Oct 20227:00 amRNSKepler Trust Intelligence: New Research

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.